Form 8-K - Current report:
SEC Accession No. 0001104659-25-080248
Filing Date
2025-08-19
Accepted
2025-08-19 16:04:53
Documents
14
Period of Report
2025-08-19
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2523903d1_8k.htm   iXBRL 8-K 25458
2 EXHIBIT 99.1 tm2523903d1_ex99-1.htm EX-99.1 20809
6 GRAPHIC tm2523903d1_ex99-1img001.jpg GRAPHIC 9210
  Complete submission text file 0001104659-25-080248.txt   230380

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cldx-20250819.xsd EX-101.SCH 3047
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20250819_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20250819_pre.xml EX-101.PRE 22380
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2523903d1_8k_htm.xml XML 3591
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)